Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Blankenfelde-Mahlow – page 67

1 867 clinical trials in Blankenfelde-Mahlow, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Blankenfelde-Mahlow at a glance
1 867
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 867 trials in Blankenfelde-Mahlow

Open in trial search

Autoimmune myositis

Not yet recruiting

A study to evaluate the safety and effectiveness of CABA-201, fludarabine, and cyclophosphamide in patients with active inflammatory myopathy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:CABA-201
  • Sponsor:Cabaletta Bio Inc.

A study to evaluate the effectiveness and safety of AP707 in patients with borderline personality disorder.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Adezunap
  • Sponsor:Apurano Pharmaceuticals GmbH

Embolism

Not yet recruiting

A study to evaluate the effectiveness of REGN7508 for preventing blood clots in adults with solid tumors undergoing cancer treatment.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg4 S228P Monoclonal Antibody Against Factor Xi And Activated Factor Xi
  • Sponsor:Regeneron Pharmaceuticals Inc.

Hepatocellular carcinoma

Not yet recruiting

A study to evaluate the safety and effectiveness of PF-08634404 and ipilimumab in adults with advanced or spreading liver cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Pfizer Inc.

Acute lymphocytic leukaemia+1

Not yet recruiting

A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia.

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Amgen Inc.

Pulmonary hypertension

Not yet recruiting

A study to evaluate the effectiveness of levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Levosimendan
  • Sponsor:Tenax Therapeutics Inc.

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Glioblastoma

Not yet recruiting

Phase 3 Randomized Study of Niraparib Tosilate Monohydrate vs. Temozolomide in Newly Diagnosed MGMT Unmethylated Glioblastoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Neurotrials LLC

A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ponsegromab
  • Sponsor:Pfizer Inc.

Uveal melanoma

Not yet recruiting

A study comparing RP2 with nivolumab versus ipilimumab with nivolumab in adults with metastatic uveal melanoma not previously treated with immune checkpoint inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Replimune Inc.

Major depression

Not yet recruiting

A study of azetukalner compared to placebo for adults with moderate-to-severe major depressive disorder

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Testing continuous versus intermittent treatment with cetuximab, fluorouracil, folinic acid, and irinotecan in patients with newly diagnosed metastatic colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Blankenfelde-Mahlow

What the registry says about research in the country

01 Psoriasis Research

Comprehensive studies evaluating new therapeutic approaches for moderate to severe plaque psoriasis, including multiple clinical trials testing novel treatments and comparing their effectiveness to existing options.

  • Treatment evaluation studies
  • Long-term safety assessments
  • Comparative efficacy research

Multiple promising compounds being investigated to expand treatment options for patients with persistent symptoms.

02 Atopic Dermatitis Studies

Innovative research focusing on moderate to severe atopic dermatitis, investigating both standalone treatments and combination therapies with topical corticosteroids.

  • Novel biological therapies
  • Dose optimization studies
  • Adolescent and adult treatments

Emphasis on developing solutions for patients who haven't responded well to conventional treatments.

03 Specialized Dermatological Conditions

Research encompassing various skin conditions including chronic hand eczema, vitiligo, and hidradenitis suppurativa.

  • Targeted therapies
  • Novel treatment approaches
  • Long-term management strategies

Focus on developing effective treatments for conditions that significantly impact quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.